Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Extended-Release Naltrexone Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

NCT04454411
View directory record Official record
Conditions
Opioid Dependence
Interventions
Brixadi, Vivitrol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

NCT01227044
View directory record Official record
Conditions
Reduction in Heavy Drinking in Patients With HIV
Interventions
Naltrexone, Placebo + Medication Management/Medication Coaching
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 26, 2026, 4:45 PM EDT
Recruiting Phase 4 Interventional

Naltrexone in AUD Reward Drinkers

NCT05028062
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

NCT03275350
View directory record Official record
Conditions
Opioid-use Disorder, Hiv
Interventions
Naltrexone Injectable Suspension, Treatment as usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Tarzana, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 26, 2026, 4:45 PM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

NCT02454712
View directory record Official record
Conditions
Healthy
Interventions
PF614, Oxycodone extended-release, Naltrexone Hydrochloride
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 26, 2026, 4:45 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

NCT07398404
View directory record Official record
Conditions
Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions
Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 26, 2026, 4:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

NCT04408313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B, XR-NTX
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 26, 2026, 4:45 PM EDT
Recruiting Not applicable Interventional

The Youth Opioid Recovery Support (YORS) Intervention

NCT04173416
View directory record Official record
Conditions
Opioid-use Disorder, Medication Adherence
Interventions
Youth Opioid Recovery Support (YORS)
Behavioral
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years to 28 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 26, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Alcohol Disorder hOsPital Treatment Trial

NCT02478489
View directory record Official record
Conditions
Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions
Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

NCT02926482
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Prescriber Recruitment Bundle (PRB)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Tallahassee, Florida • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone

NCT00577408
View directory record Official record
Conditions
Opiate Dependence, Heroin Dependence
Interventions
depot naltrexone, Oral Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 26, 2026, 4:45 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

NCT02680847
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
ALO-02
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone for Alcohol Dependence in Primary Care

NCT00620750
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Extended release injectable naltrexone (Vivitrol)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 26, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Device · Drug
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rancho Mirage, California • Crownsville, Maryland • Center City, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 26, 2026, 4:45 PM EDT